open access publication

Article, 2024

Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology

Acta Neuropathologica, ISSN 0001-6322, Volume 147, 1, 10.1007/s00401-023-02682-x

Contributors

Godicke S. [1] [2] Kresbach C. [1] [2] Ehlert M. [1] [2] Obrecht D. [1] Altendorf L. [1] [2] Hack K. [1] [2] von Hoff K. 0000-0002-5669-8546 [3] [4] Caren H. 0000-0002-8584-555X [5] Melcher V. [6] Kerl K. 0000-0002-5676-8102 [6] Englinger B. [7] [8] [9] Filbin M. [7] [8] Pajtler K.W. 0000-0002-3562-6121 [10] [11] [12] Gojo J. 0000-0002-8113-3416 [9] Pietsch T. [13] Rutkowski S. [1] Schuller U. 0000-0002-8731-1121 (Corresponding author) [1] [2]

Affiliations

  1. [1] University Medical Center Hamburg-Eppendorf
  2. [NORA names: Germany; Europe, EU; OECD];
  3. [2] Research Institute Children's Cancer Center
  4. [NORA names: Germany; Europe, EU; OECD];
  5. [3] Aarhus University Hospital
  6. [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  7. [4] Berlin Institute of Health
  8. [NORA names: Germany; Europe, EU; OECD];
  9. [5] Sahlgrenska Academy
  10. [NORA names: Sweden; Europe, EU; Nordic; OECD];

Abstract

Posterior fossa type A (PF-EPN-A, PFA) ependymoma are aggressive tumors that mainly affect children and have a poor prognosis. Histopathology shows significant intratumoral heterogeneity, ranging from loose tissue to often sharply demarcated, extremely cell-dense tumor areas. To determine molecular differences in morphologically different areas and to understand their clinical significance, we analyzed 113 PF-EPN-A samples, including 40 corresponding relapse samples. Cell-dense areas ranged from 0 to 100% of the tumor area and displayed a higher proportion of proliferating tumor cells (p < 0.01). Clinically, cell density was associated with poor progression-free and overall survival (p = 0.0026, p < 0.01). Molecularly, tumor areas with low and high cell density showed diverging DNA methylation profiles regarding their similarity to distinct previously discovered PF-EPN-A subtypes in 9/21 cases. Prognostically relevant chromosomal changes at 1q and 6q showed spatial heterogeneity within single tumors and were significantly enriched in cell-dense tumor areas as shown by single-cell RNA (scRNA)-sequencing as well as copy number profiling and fluorescence in situ hybridization (FISH) analyses of different tumor areas. Finally, spatial transcriptomics revealed cell-dense areas of different tumors to be more similar than various different areas of the same tumor. High-density areas distinctly overexpressed genes encoding histone proteins, WNT5A, TGFB1, or IGF2. Relapsing tumors displayed a higher proportion of cell-dense areas (p = 0.036), a change in PF-EPN-A methylation subtypes (13/32 patients), and novel chromosome 1q gains and 6q losses (12/32 cases) compared to corresponding primary tumors. Our data suggest that PF-EPN-A ependymomas habor a previously unrecognized intratumoral heterogeneity with clinical implications, which has to be accounted for when selecting diagnostic material, inter alia, by histological evaluation of the proportion of cell-dense areas.

Keywords

1q gain, 6q loss, DNA methylation, Ependymoma, Intratumoral heterogeneity, Morphology

Data Provider: Elsevier